Bioequivalence Study of Budesonide From Ekmasonid 9 mg Extended Release FCT (Hikma Pharma, Egypt) Versus Uceris 9 mg Extended Release Tablets (Man. for: Salix Pharm., a Division of Valeant Pharm. LLC, USA, by: Cosmo S.P.A., Italy by License of Cosmo Tech. Ltd., Ireland, Product of France)

NCT04854538 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Ekmasonid
DRUG: Uceris (first dose)
DRUG: Uceris (second dose)

Sponsor

Genuine Research Center, Egypt

Collaborators

[object Object]